Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development

Sun, Daqing, Li, Zhihong, Rew, Yosup, Gribble, Michael, Bartberger, Michael D., Beck, Hilary P., Canon, Jude, Chen, Ada +42 more·2014·Journal of Medicinal Chemistry
DOI 10.1021/jm401753e

Cited by (306)

Items 301–306 of 306

  1. BindingDB Entry 50044171: Selective and potent morpholinone inhibitors of the MDM2-p53 protein-protein interaction.
    BindingDB · 2015 · UC San Diego
  2. BindingDB Entry 50045252: Optimization beyond AMG 232: discovery and SAR of sulfonamides on a piperidinone scaffold as potent inhibitors of the MDM2-p53 protein-protein interaction.
    BindingDB · 2016 · UC San Diego
  3. BindingDB Entry 50007847: Development of selective small molecule MDM2 degraders based on nutlin.
    BindingDB · 2021 · UC San Diego
  4. BindingDB Entry 50044195: Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.
    BindingDB · 2015 · UC San Diego
  5. BindingDB Entry 50049084: Discovery of novel polycyclic spiro-fused carbocyclicoxindole-based anticancer agents.
    BindingDB · 2019 · UC San Diego
  6. BindingDB Entry 50019141: Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression.
    BindingDB · 2024 · UC San Diego